Revolutionary Veterinary AI Platform Ditches Dense Documentation in Favor of Clear, Engaging Video Walkthrough MINNEAPOLIS, MN, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo.ai, the AI powered platform transforming how veterinary practices connect with pet parents, today announced something different: instead of another lengthy press release filled with jargon, they made a video. "Let's be honest," said John Lai, CEO at PetVivo Holdings (OTCQX: PETV; OTCID: PETVW). "Most tech launches are too complicated and to ...

Core Insights - PetVivo.ai has launched an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [2][4][9] Group 1: Company Overview - PetVivo Holdings, Inc. is focused on commercializing innovative medical products and therapeutics for companion animals and horses [2][12] - The company has introduced PetVivo.ai, an AI-driven Software-as-a-Service (SaaS) platform that enhances its existing product portfolio [3][10] Group 2: Market Opportunity - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet parents making up 57% of pet owners, who expect modern digital experiences [4][8] - There are approximately 30,000 veterinary practices in the U.S. and over 100,000 worldwide, indicating a large and under-digitized market for PetVivo.ai [8] Group 3: Product and Technology - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with pet owners, improving lead generation and customer engagement [5][10] - The platform has demonstrated a customer acquisition cost of $42.53, significantly lower than the typical $80–$400 spent by veterinary practices [2][7] Group 4: Financial Metrics - In a beta program, the median practice acquired 47 new clients over six months, achieving a blended customer acquisition cost of $42.53 [5][7] - The platform offers a pricing model starting at $1,999 per month, with gross margins between 80% and 90% [7] Group 5: Competitive Advantages - PetVivo.ai holds a first-mover advantage in the AI-driven veterinary market, with no direct competitors and strong network effects [10] - The company has established relationships with 1,200 veterinary clinic distributors and plans to expand to over 7,000 [10] Group 6: Valuation Potential - The launch of PetVivo.ai is expected to transition the company from traditional medical device revenue multiples (1–2x) to AI SaaS multiples (15–30x), indicating potential valuation upside [9]

Core Insights - PetVivo Holdings, Inc. will hold a conference call on November 14, 2025, to discuss its fiscal second quarter results for the period ending September 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary PetVivo Animal Health, Inc., specializing in biomedical devices for companion animals [4] - The company aims to bring veterinary medical devices to market faster than more regulated pharmaceuticals, enhancing revenue timelines [4] - PetVivo holds a portfolio of twelve patents and six trade secrets protecting its biomaterials and products [5] Upcoming Events - The conference call will include a presentation by management followed by a Q&A session [2] - Dial-in information for the conference call includes a toll-free number and a specific conference ID and passcode [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - PetVivo Holdings, Inc. has entered into a 10-year exclusive white-label licensing agreement with Digital Landia Holding Corp for the Agentic Pet AI technology, aimed at addressing high client acquisition costs and engaging the growing Gen Z pet parent demographic [1][13]. Industry Overview - The veterinary industry is experiencing a demographic shift, with Gen Z pet parenthood increasing by 43.5% in 2024, making Gen Z and Millennials account for 57% of all pet parents in the U.S. [3][5]. - Traditional marketing strategies in veterinary practices are failing to connect with the tech-savvy Gen Z demographic, which presents a significant opportunity for innovative solutions [5]. Technology and Solutions - The Agentic Pet AI technology can reduce client acquisition costs by 90% to 98%, lowering costs from $50-$150+ per client to just $1.50-$5.00 per targeted outreach [2][9]. - The technology includes a freemium app with nine specialized AI diagnostic agents that track pet health, allowing pet parents to share health data seamlessly with veterinary practices [7][8]. Economic Impact - The partnership is expected to transform client acquisition for veterinary practices, with a case study showing a reduction in acquisition costs from $80-$120 to $3.50 per client, alongside significant time savings in patient history gathering [11][12]. - The overall efficiency of consultations is projected to improve by 20%, with a 30% increase in preventive care visits due to early issue identification through AI [12]. Market Opportunity - PetVivo is entering a $4.9 billion U.S. veterinary AI market with over 30,000 addressable clinics, leveraging existing relationships with more than 1,000 veterinary clinics for immediate distribution [14]. - The company reported a 141% year-over-year growth in Q1 FY2026, with fiscal 2025 revenue reaching $1.13 million, indicating strong market momentum [14]. Strategic Positioning - The exclusive agreement provides PetVivo with a competitive advantage for 10 years, creating multiple revenue streams through B2B subscriptions and lead generation fees [15]. - The dual-platform launch in Q1 2026 is expected to create immediate network effects, enhancing the value proposition for both pet parents and veterinary practices [13].

Core Insights - PetVivo Holdings, Inc. has entered into note conversion agreements with four existing shareholders to convert $2,018,155 of outstanding promissory notes into 3,669,806 shares of common stock, effectively eliminating over $2 million of debt from its balance sheet [1][4] Group 1: Financial Developments - The total outstanding debt consisted of a principal amount of $1,850,000 and accrued interest of $168,155 [1] - The conversion prices of the notes ranged from $0.50 to $0.75 per share [1] - The successful completion of the note conversion strengthens the company's financial position and allows for more resources to be directed towards product commercialization [4] Group 2: Product Information - PetVivo's signature products include SPRYNG with OsteoCushion Technology, an injectable veterinary medical device that aids in managing joint pain and restoring joint mechanics [2][7] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for intra-articular administration in dogs and horses, providing a consistent dose of 4 billion platelets per vial [3][7] Group 3: Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [6] - The company has a robust pipeline of products protected by twelve patents and six trade secrets [7]

Core Points - PetVivo Holdings, Inc. will hold a conference call on August 14, 2025, to discuss its fiscal first quarter results for the period ending June 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary, PetVivo Animal Health, Inc., and is dedicated to the manufacturing, commercialization, and licensing of biomedical devices for animals [4] - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and products [5] Conference Call Details - The conference call will take place at 5:00 p.m. Eastern time, with a toll-free dial-in number provided for participants [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - Digital Landia, in collaboration with PetVivo Holdings and its subsidiary, is set to launch AgenticPet.ai, the first autonomous pet care AI ecosystem, on May 23, 2025, aimed at transforming pet health and wellness through specialized AI agents [1][2] Group 1: Technology and Innovation - AgenticPet.ai utilizes multi-agent technology to create self-learning AI agents that provide insights into pet health, behavior, and nutrition [2][3] - The platform features specialized agents for veterinary diagnostics, behavioral analysis, nutritional advice, emotional wellness, and IoT data integration, enhancing comprehensive pet care [5][4] - The AI agents undergo rigorous digital certification exams to ensure expert-level mastery in various domains related to pet care [3] Group 2: Business Model and Market Strategy - AgenticPet.ai will adopt a tiered pricing structure, including a freemium tier, a premium subscription at $9.95/month, and an elite package at $24.95/month, making the technology accessible to a wide range of pet owners [4][5] - The platform is expected to onboard 100,000 freemium users within six months of launch, with a conservative estimate of a 10% conversion rate to paid subscriptions, potentially generating nearly $2 million in annual recurring revenue [7] Group 3: Strategic Positioning - PetVivo Holdings aims to align its clinically proven therapies with the innovative AI technology of AgenticPet.ai, enhancing its visibility and value in the veterinary care market [8] - The company focuses on leveraging human therapies for companion animals, which allows for a quicker market entry compared to more regulated pharmaceuticals [10]